Upon engulfment of dying tumour cells, APCs undergo activation and maturation characterised by upregulation of major histocompatibility complex class II molecules and costimulatory markers, such as CD80 and CD86, while migrating to the tumour-draining lymph nodes to present cancer antigens to CD8+ T cells. Here, CD86 is linked to neoplasm.